For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

the new investigation is intended to inform future clinical trials by including different dosages of the gene therapy, tests in male and female mice, and examinations in early- and late-onset ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...